Status:
COMPLETED
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)
Lead Sponsor:
Janssen-Cilag B.V.
Conditions:
Anemia
Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
The main purpose of this study is to evaluate the safety and efficacy (% response) of epoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.
Detailed Description
Anemia has been identified as a common complication and a widespread problem in the cancer population. Anemia is a condition in which a patient has below normal levels of hemoglobin, the substance in ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of solid tumors, multiple myeloma (Kahlers' disease), non-Hodgkin lymphoma or Hodgkins' disease
- Patients must already be receiving chemotherapy or start their first cycle within a week of enrollment
- Patients must receive epoetin alfa treatment (expected treatment duration is at least 4 weeks)
Exclusion
- Patients who cannot read the Dutch language and/or do not understand the Dutch Informed Consent Form and patients participating in either of our observational studies, EVALUATE or COMPARE
Key Trial Info
Start Date :
October 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
1927 Patients enrolled
Trial Details
Trial ID
NCT00398749
Start Date
October 1 2005
End Date
November 1 2009
Last Update
November 6 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.